Advances in Collaborative Practice for Patients With Head and Neck Cancers
November 5, 2016
- Demonstrate increased understanding of the mechanisms of tumor immune escape and their role in cancer disease progression as well as the mechanisms of action (MOAs) of immunotherapy used in the treatment of HNSCC.
- Monitor for and manage adverse effects of immune checkpoint inhibitor therapy and EGFR-directed therapy in the treatment of patients with recurrent or metastatic HNSCC.
Gaylord National Hotel
National Harbor, MD
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC